Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the attention-deficit/hyperactivity disorder (ADHD) drug market in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan will fluctuate modestly over the next decade, decreasing from $5 billion in 2009 to a trough in 2013 before climbing to $4.1 billion in 2019...
More...
More...